AAAAAA

   
Results: 1-25 | 26-35
Results: 1-25/35
Blocking oncogenic Ras signaling for cancer therapy
Authors: Adjei, AA
Citation: Aa. Adjei, Blocking oncogenic Ras signaling for cancer therapy, J NAT CANC, 93(14), 2001, pp. 1062-1074
Ras signaling pathway proteins as therapeutic targets
Authors: Adjei, AA
Citation: Aa. Adjei, Ras signaling pathway proteins as therapeutic targets, CUR PHARM D, 7(16), 2001, pp. 1581-1594
Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines
Authors: Adjei, AA Davis, JN Bruzek, LM Erlichman, C Kaufmann, SH
Citation: Aa. Adjei et al., Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines, CLIN CANC R, 7(5), 2001, pp. 1438-1445
Current status of clinical trials of farnesyltransferase inhibitors
Authors: Karp, JE Kaufmann, SH Adjei, AA Lancet, JE Wright, JJ End, DW
Citation: Je. Karp et al., Current status of clinical trials of farnesyltransferase inhibitors, CURR OPIN O, 13(6), 2001, pp. 470-476
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks
Authors: Alberts, SR Erlichman, C Sloan, J Okuno, SH Burch, PA Rubin, J Pitot, HC Goldberg, RM Adjei, AA Atherton, PJ Kaufmann, SH
Citation: Sr. Alberts et al., Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks, ANN ONCOL, 12(5), 2001, pp. 627-631
Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2 '-deoxyuridine (IdUrd)
Authors: Galanis, E Goldberg, R Reid, J Atherton, P Sloan, J Pitot, H Rubin, J Adjei, AA Burch, P Safgren, SL Witzig, TE Ames, MM Erlichman, C
Citation: E. Galanis et al., Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2 '-deoxyuridine (IdUrd), ANN ONCOL, 12(5), 2001, pp. 701-707
Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566
Authors: Erlichman, C Adjei, AA Alberts, SR Sloan, JA Goldberg, RM Pitot, HC Rubin, J Atherton, PJ Klee, GG Humphrey, R
Citation: C. Erlichman et al., Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566, ANN ONCOL, 12(3), 2001, pp. 389-395
Gemcitabine and pemetrexed disodium in treatment breast cancer
Authors: Adjei, AA
Citation: Aa. Adjei, Gemcitabine and pemetrexed disodium in treatment breast cancer, ONCOLOGY-NY, 15(2), 2001, pp. 34-37
Systemic chemotherapy in patients with renal failure
Authors: Bekele, L Vazquez, MV Adjei, AA
Citation: L. Bekele et al., Systemic chemotherapy in patients with renal failure, AM J CL ONC, 24(4), 2001, pp. 382-384
Human 3 '-phosphoadenosine 5 '-phosphosulfate synthetase: Radiochemical enzymatic assay, biochemical properties and hepatic variation (vol 29, pg 172, 2001)
Authors: Xu, ZH Wood, TC Adjei, AA Weinshilboum, RM
Citation: Zh. Xu et al., Human 3 '-phosphoadenosine 5 '-phosphosulfate synthetase: Radiochemical enzymatic assay, biochemical properties and hepatic variation (vol 29, pg 172, 2001), DRUG META D, 29(4), 2001, pp. 466-466
Human 3 '-phosphoadenosine 5 '-phosphosulfate synthetase: Radiochemical enzymatic assay, biochemical properties, and hepatic variation
Authors: Xu, ZH Wood, TC Adjei, AA Weinshilboum, RM
Citation: Zh. Xu et al., Human 3 '-phosphoadenosine 5 '-phosphosulfate synthetase: Radiochemical enzymatic assay, biochemical properties, and hepatic variation, DRUG META D, 29(2), 2001, pp. 172-178
The pharmacologic basis of high dose chemotherapy with haematopoietic stemcell support for solid tumours
Authors: Porrata, LF Adjei, AA
Citation: Lf. Porrata et Aa. Adjei, The pharmacologic basis of high dose chemotherapy with haematopoietic stemcell support for solid tumours, BR J CANC, 85(4), 2001, pp. 484-489
A primer of chemotherapy
Authors: Adjei, AA
Citation: Aa. Adjei, A primer of chemotherapy, PRIMARY HEMATOLOGY, 2001, pp. 379-406
Signal transduction pathway targets for anticancer drug discovery
Authors: Adjei, AA
Citation: Aa. Adjei, Signal transduction pathway targets for anticancer drug discovery, CUR PHARM D, 6(4), 2000, pp. 361-378
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
Authors: Pitot, HC Goldberg, RM Reid, JM Sloan, JA Skaff, PA Erlichman, C Rubin, J Burch, PA Adjei, AA Alberts, SA Schaaf, LJ Elfring, G Miller, LL
Citation: Hc. Pitot et al., Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy, CLIN CANC R, 6(6), 2000, pp. 2236-2244
Comparison of potential markers of farnesyltransferase inhibition
Authors: Adjei, AA Davis, JN Erlichman, C Svingen, PA Kaufmann, SH
Citation: Aa. Adjei et al., Comparison of potential markers of farnesyltransferase inhibition, CLIN CANC R, 6(6), 2000, pp. 2318-2325
Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors
Authors: Adjei, AA
Citation: Aa. Adjei, Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors, ANN ONCOL, 11(10), 2000, pp. 1335-1341
The Schilsky article reviewed
Authors: Adjei, AA
Citation: Aa. Adjei, The Schilsky article reviewed, ONCOLOGY-NY, 14(9), 2000, pp. 1309-1310
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
Authors: Adjei, AA Erlichman, C Sloan, JA Reid, JM Pitot, HC Goldberg, RM Peethambaram, P Atherton, P Hanson, LJ Alberts, SR Jett, J
Citation: Aa. Adjei et al., Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors, J CL ONCOL, 18(8), 2000, pp. 1748-1757
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity
Authors: Adjei, AA Klein, CE Kastrissios, H Goldberg, RM Alberts, SR Pitot, HC Sloan, JA Reid, JM Hanson, LJ Atherton, P Rubin, J Erlichman, C
Citation: Aa. Adjei et al., Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity, J CL ONCOL, 18(5), 2000, pp. 1116-1123
Protein farnesyl transferase as a target for the development of anticancerdrugs
Authors: Adjei, AA
Citation: Aa. Adjei, Protein farnesyl transferase as a target for the development of anticancerdrugs, DRUG FUTURE, 25(10), 2000, pp. 1069-1079
gamma delta(+) T cells and 65-kDa heat shock protein expression following Cryptosporidium parvum challenge in athymic C57BL/6J nude mice
Authors: Adjei, AA Curran, BC Castro, M Shrestha, AK Delsid, L Fritz, H Velez, M Enriquez, FJ
Citation: Aa. Adjei et al., gamma delta(+) T cells and 65-kDa heat shock protein expression following Cryptosporidium parvum challenge in athymic C57BL/6J nude mice, IMMUNOL LET, 72(1), 2000, pp. 35-38
A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
Authors: Adjei, AA Erlichman, C Davis, JN Cutler, DL Sloan, JA Marks, RS Hanson, LJ Svingen, PA Atherton, P Bishop, WR Kirschmeier, P Kaufmann, SH
Citation: Aa. Adjei et al., A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity, CANCER RES, 60(7), 2000, pp. 1871-1877
Adoptive transfer of immunity with intraepithelial lymphocytes in Cryptosporidium parvum-infected severe combined immunodeficient mice
Authors: Adjei, AA Shrestha, AK Castro, M Enriquez, FJ
Citation: Aa. Adjei et al., Adoptive transfer of immunity with intraepithelial lymphocytes in Cryptosporidium parvum-infected severe combined immunodeficient mice, AM J MED SC, 320(5), 2000, pp. 304-309
Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors
Authors: Pitot, HC McElroy, EA Reid, JR Windebank, AJ Sloan, JA Erlichman, C Bagniewski, PG Walker, DL Rubin, J Goldberg, RM Adjei, AA Ames, MM
Citation: Hc. Pitot et al., Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors, CLIN CANC R, 5(3), 1999, pp. 525-531
Risultati: 1-25 | 26-35